Montreal / April 05, 2024 - NexPlasmaGen is pleased to announce that on February 6, 2024, the 2nd U.S. patent (US 11895763B2) was granted for its medical technology developed for the treatment of breast cancer. NexPlasmaGen has exclusive rights to this patent under license from...
Montreal / April 21, 2023 - NexPlasmaGen announces that it has received $511,186 in funding from the ministère de l'économie, de l'innovation et de l’Énergie (MEIE) du Québec and the Québec Breast Cancer Foundation (QBCF) to conduct clinical safety trials with its Convertible Plasma Jet...
NEXPLASMAGEN TO PRESENT AT THE 2023 OBIO INVESTMENT SUMMIT Canada’s Premier Health Science Investment Event! Montreal/February 2, 2022 – NexPlasmaGen is proud to announce that it is presenting at 2023 OBIO Investment Summit. The OBIO Investment Summit will be hosted at the World Trade Centre Toronto on February...
Montreal / July 4, 2022 NexPlasmaGen is a finalist for the ADRIQ Innovation Award 2022 in the category Innovation from Public Research. The Innovation Awards Gala has become a must-attend event in the Quebec ecosystem. The 32nd ADRIQ Innovation Awards Gala will take place on Thursday, November...
Montreal/June 23, 2022 – NexPlasmaGen is honored to present at the MedInvest Oncology Investor Conference. The MedInvest Oncology Investor Conference will be hosted in person June 28-29, 2022 in New York City at the One Vanderbilt Avenue. NexPlasmaGen was selected to present on June 28 at...
NEXPLASMAGEN TO PRESENT AT THE 2022 OBIO INVESTMENT SUMMIT Canada’s Premier Health Science Investment Event! Montreal/January 30, 2022 – NexPlasmaGen is proud to announce that it is presenting at 2022 OBIO Investment Summit. The OBIO Investment Summit will be hosted virtually February 9-11, 2022, and NexPlasmaGen was selected...
NEXPLASMAGEN TO PRESENT AT SEED SHOWCASE 2022 NexPlasmaGen will pitch its business opportunity to investors! Montreal/December 24 – NexPlasmaGen, today announced that it is presenting at Seed Showcase, part of the Biotech Showcase™ 2022 conference. This year, in addition to seeing NexPlasmaGen scheduled presentation delivered onsite via...
NexPlasmaGen is proud to announce that the preclinical trials program led by Dr. Philip Wong at the Centre Hospitaller de l’Université de Montréal was successfully completed. The first stage of the program demonstrated that NexPlasmaGen's Convertible Plasma Jet (CPJ) was able to destroy breast cancer...
NexPlasmaGen Inc. is pleased to announce that its patented cold plasma technology is in preparation for clinical investigation for the treatment of breast cancer. NexPlasmaGen has recently received financial support from private investors, NRC-IRAP and the Quebec Ministry of Economy and Innovation for a total...
NexPlasmaGen Inc. is pleased to announce the completion of $795,000 in private and public investment from individuals, Aligo Innovation, the Quebec MEDTEQ program and the federal MITACS and CNRC-IRAP programs to accelerate the development of its patented cold plasma technology, the APGDT, as an adjuvant...